Can Auvelity (dextromethorphan/bupropion) be co‑administered with ketamine for depression, and what are the safety concerns?

Link Between Auvelity and Ketamine

Mechanistic Relationship

Auvelity (dextromethorphan/bupropion) was developed as an oral alternative to ketamine, sharing the same NMDA receptor antagonism mechanism that produces rapid antidepressant effects, but with a more favorable safety profile for routine clinical use. 1

Shared Pharmacological Properties

• Both dextromethorphan (the active component in Auvelity) and ketamine function as NMDA receptor antagonists, blocking glutamatergic signaling to produce rapid antidepressant effects 1, 2
• Dextromethorphan shares multiple pharmacological targets with ketamine including NMDA receptors, μ opiate receptors, sigma-1 receptors, calcium channels, and serotonin transporter sites 2
• Both agents increase AMPA-to-NMDA receptor activity ratio, leading to synaptic plasticity changes that rapidly improve mood 3, 2

Clinical Development Context

• Auvelity was specifically developed as part of "post-ketamine era" drug discovery efforts to create agents with ketamine-like antidepressant profiles but with reduced adverse effects 1
• The FDA approved Auvelity in August 2022 for major depressive disorder in adults, representing the first oral NMDA antagonist antidepressant to reach market following ketamine's validation of the glutamatergic hypothesis 4

Co-Administration Safety Concerns

Co-administering Auvelity with ketamine is not recommended due to overlapping NMDA receptor antagonism, which would create additive dissociative and psychotomimetic effects without clear evidence of enhanced therapeutic benefit.

Overlapping Mechanisms Create Risk

• Both agents block NMDA receptors through similar mechanisms, creating potential for excessive glutamatergic modulation 1, 2
• Ketamine produces dose-dependent psychotomimetic effects including hallucinations (20% at 0.5 mg/kg) and nightmares (12% at 0.5 mg/kg) 5, 3
• Adding dextromethorphan's NMDA antagonism would likely amplify these dissociative effects without established safety data 1

Lack of Evidence for Combination

• No clinical trials have examined the safety or efficacy of combining Auvelity with ketamine 6
• The clinical development of Auvelity was designed as an alternative to ketamine, not as an adjunct therapy 1, 4
• Studies of dextromethorphan combinations have only examined dextromethorphan with quinidine or bupropion, not with other NMDA antagonists 6

Clinical Decision Algorithm

When to Use Ketamine

• Acute suicidal ideation requiring rapid intervention: Use IV ketamine 0.5 mg/kg over 40 minutes, with effects beginning within 40 minutes 5, 7, 3
• Treatment-resistant depression requiring immediate response: Use IV ketamine 0.5 mg/kg twice weekly until remission or 4-6 total infusions 7
• Emergency department presentations: Consider lower dose ketamine 0.2 mg/kg over 1-2 minutes for rapid SI reduction 5, 7

When to Use Auvelity

• Major depressive disorder requiring rapid but outpatient-manageable treatment: Auvelity 45-105 mg daily produces significant MADRS reductions within 2 weeks 8
• Patients unable to access ketamine infusion centers: Auvelity provides oral administration with better tolerability than ketamine 1, 8
• Long-term maintenance therapy: Auvelity maintains remission rates approaching 70% through 12-15 months 8

Sequential Use Strategy

If a patient has received acute ketamine treatment for suicidal ideation or severe depression, transition to Auvelity for maintenance therapy rather than combining the two agents.

• Allow complete washout of ketamine effects (2-3 days after last infusion) before initiating Auvelity 3
• Monitor for residual dissociative symptoms before starting dextromethorphan-based therapy 1
• Use Auvelity as the ongoing oral maintenance treatment to sustain ketamine's initial rapid response 8

Key Clinical Pitfalls

• Avoid assuming Auvelity can substitute for ketamine in acute suicidal crises: Ketamine's 40-minute onset for antisuicidal effects is unmatched by any oral agent 5, 3
• Do not combine NMDA antagonists without safety data: The additive psychotomimetic burden could be dangerous and is unstudied 1, 2
• Recognize that Auvelity's rapid onset (2 weeks) is still slower than ketamine's (40 minutes to 24 hours): Choose the agent based on urgency of clinical need 3, 8